home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

2.200 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Stocks That Hit 52-Week Lows On Thursday ↗

January 12, 2023

On Thursday, 13 stocks hit new 52-week lows.

Via Benzinga

Top 5 Health Care Stocks That May Surge ↗

January 10, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC ↗

January 06, 2023

Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.

Via InvestorPlace

8 Analysts Have This to Say About Century Therapeutics ↗

January 06, 2023

Via Benzinga

Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive ↗

January 06, 2023

Via Benzinga

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

January 05, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022 ↗

December 27, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Century Therapeutics, Inc.

Via GlobeNewswire

Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday ↗

December 20, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved ↗

November 22, 2022

This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...

Via Benzinga

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

November 11, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 10, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

November 02, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Century Therapeutics to Present at the SITC 37th Annual Meeting

October 05, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

October 03, 2022

From Century Therapeutics, Inc.

Via GlobeNewswire

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 25, 2022

Via Benzinga

FDA Announced Clearance To Century Therapeutics' Allogeneic Cell Therapy Candidate Study ↗

August 25, 2022

Century Therapeutics, Inc. (NASDAQ: IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or...

Via Benzinga

U.S. Stock Futures Higher Following Friday's Rally ↗

June 27, 2022

Pre-open movers

Via Benzinga

92 Biggest Movers From Friday ↗

May 09, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...

Via Benzinga

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch ↗

February 08, 2022

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 01, 2022

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K...

Via Benzinga

45 Stocks Moving In Monday's Mid-Day Session ↗

January 10, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired...

Via Benzinga

60 Biggest Movers From Yesterday ↗

January 11, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 10, 2022

Gainers Molecular Partners (NASDAQ:MOLN) shares rose 26.6% to $20.9 during Monday's pre-market session. The company's market cap stands at $674.6 million. Apria (...

Via Benzinga

Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies ↗

January 10, 2022

Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to...

Via Benzinga

Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies

January 10, 2022

From Bristol Myers Squibb

Via Business Wire

51 Biggest Movers From Yesterday ↗

December 28, 2021

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com